Irinotecan for Germ Cell Cancer
Author Information
Author(s): Powles T, Shamash J, Berney D, Oliver R T D
Primary Institution: St Bartholomew's Hospital
Hypothesis
Can irinotecan be effective in patients with relapsed or cisplatin-refractory germ cell cancer?
Conclusion
Combining drugs with low single-agent activity can lead to improved results in patients with germ cell cancer.
Supporting Evidence
- Previous studies showed low response rates to single-agent irinotecan.
- Combination chemotherapy improved overall survival in other studies.
- Four patients achieved complete remissions with the new treatment regimen.
Takeaway
Doctors are trying a mix of medicines to help patients with a tough type of cancer, and it seems to be working better than just one medicine alone.
Methodology
Patients received a combination of oxaliplatin, irinotecan, and paclitaxel every 21 days.
Limitations
The study involved a small number of patients and was conducted in a highly refractory population.
Participant Demographics
Patients were heterogenous, most had received prior high-dose therapy, and many were refractory to cisplatin-based therapy.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website